UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Au Nanomatryoshkas as Efficient Near-Infrared Photothermal Transducers for Cancer Treatment: Benchmarking against Nanoshells

ACS nano, 2014-06, Vol.8 (6), p.6372-6381

2014

Volltextzugriff (PDF)

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer

Proceedings of the National Academy of Sciences - PNAS, 2019-12, Vol.116 (52), p.26823-26834

2019

Volltextzugriff (PDF)

NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer

Scientific reports, 2022-02, Vol.12 (1), p.1972-1972, Article 1972

2022

Volltextzugriff (PDF)

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer

The FASEB journal, 2021-07, Vol.35 (7), p.e21719-n/a

2021

Volltextzugriff (PDF)

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

Cell reports (Cambridge), 2023-08, Vol.42 (8), p.112821-112821, Article 112821

2023

Volltextzugriff (PDF)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

NPJ breast cancer, 2021-05, Vol.7 (1), p.63-63, Article 63

2021

Volltextzugriff (PDF)

Emergency management systems using mobile cloud computing: A survey

International journal of communication systems, 2023-08, Vol.36 (12), p.n/a

2023

Volltextzugriff (PDF)

Sub-100nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors

Journal of controlled release, 2014-10, Vol.191, p.90-97

2014

Volltextzugriff (PDF)

Flood Prediction with Optimized Attributes and Clustering

Computación y Sistemas, 2023-01, Vol.27 (4), p.1157-1167

2023

Volltextzugriff (PDF)

BETA2 Activates Transcription From the Upstream Glucokinase Gene Promoter in Islet β-Cells and Gut Endocrine Cells

Diabetes (New York, N.Y.), 2003-02, Vol.52 (2), p.403-408

2003

Volltextzugriff (PDF)

Sub-100 nm Gold Nanomatryoshkas Improve Photo-thermal Therapy Efficacy in Large and Highly Aggressive Triple Negative Breast Tumors

Journal of controlled release, 2014-10, Vol.191, p.90-97

2014

Volltextzugriff (PDF)

SMedia: social media data analysis for emergency detection and its type identification

International journal of computational science and engineering, 2023, Vol.26 (4), p.385-396

2023

Volltextzugriff (PDF)

Title SMedia: social media data analysis for emergency detection and its type identification

International journal of computational science and engineering, 2023, Vol.1 (1), p.1

2023

Volltextzugriff (PDF)

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer

The FASEB journal, 2021-05, Vol.35 (S1), p.n/a, Article fasebj.2021.35.S1.00353

2021

Volltextzugriff (PDF)

Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS5-29-PS5-29

2021

Volltextzugriff (PDF)

Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD8-03-PD8-03

2021

Volltextzugriff (PDF)

Abstract PD3-09: HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD3-09-PD3-09

2021

Volltextzugriff (PDF)

Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD1-05-PD1-05

2022

Volltextzugriff (PDF)

Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD8-06-PD8-06

2022

Volltextzugriff (PDF)

Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1911-1911

2020

Volltextzugriff (PDF)

Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer

Molecular cancer research, 2019-11, Vol.17 (11), p.2318-2330

2019

Volltextzugriff (PDF)

Abstract 1077: Acquired neratinib resistance is associated with acquisition of HER2 and PIK3CA mutations and can be overcome using potent drug combinations in HER2-positive breast cancer models

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1077-1077

2021

Volltextzugriff (PDF)

Abstract P2-03-10: DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P2-P2-03-10

2023

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Au Nanomatryoshkas as Efficient Near-Infrared Photothermal Transducers for Cancer Treatment: Benchmarking against Nanoshells

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer

NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2 + Breast Cancer

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

Emergency management systems using mobile cloud computing: A survey

Sub-100nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors

Flood Prediction with Optimized Attributes and Clustering

BETA2 Activates Transcription From the Upstream Glucokinase Gene Promoter in Islet β-Cells and Gut Endocrine Cells

Sub-100 nm Gold Nanomatryoshkas Improve Photo-thermal Therapy Efficacy in Large and Highly Aggressive Triple Negative Breast Tumors

SMedia: social media data analysis for emergency detection and its type identification

Title SMedia: social media data analysis for emergency detection and its type identification

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer

Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC)

Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer

Abstract PD3-09: HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models

Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer

Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer

Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models

Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer

Abstract 1077: Acquired neratinib resistance is associated with acquisition of HER2 and PIK3CA mutations and can be overcome using potent drug combinations in HER2-positive breast cancer models

Abstract P2-03-10: DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

Suchergebnisse filtern